Kathleen T. Brady M.D. Ph.D. Frances R. Levin M.D. - The American Psychiatric Association Publishing Textbook of Substance Use Disorder Treatment, Sixth Edition

SIXTH EDITION

SIXTH EDITION

EDITED BY

Kathleen T. Brady, M.D., Ph.D.

Frances R. Levin, M.D.

Marc Galanter, M.D.

Herbert D. Kleber, M.D.

Note: The authors have worked to ensure that all information in this book is accurate at the time of publication and consistent with general psychiatric and medical standards, and that information concerning drug dosages, schedules, and routes of administration is accurate at the time of publication and consistent with standards set by the U.S. Food and Drug Administration and the general medical community. As medical research and practice continue to advance, however, therapeutic standards may change. Moreover, specific situations may require a specific therapeutic response not included in this book. For these reasons and because human and mechanical errors sometimes occur, we recommend that readers follow the advice of physicians directly involved in their care or the care of a member of their family.

Books published by American Psychiatric Association Publishing represent the findings, conclusions, and views of the individual authors and do not necessarily represent the policies and opinions of American Psychiatric Association Publishing or the American Psychiatric Association.

If you wish to buy 50 or more copies of the same title, please go to www.appi.org/specialdiscounts for more information.

Copyright 2021 American Psychiatric Association Publishing

ALL RIGHTS RESERVED

Sixth Edition

Manufactured in the United States of America on acid-free paper
252423222154321

American Psychiatric Association Publishing
800 Maine Avenue SW Suite 900
Washington, DC 20024-2812
www.appi.org

Library of Congress Cataloging-in-Publication Data

Names: Brady, Kathleen, 1952 editor. | Levin, Frances R., editor. | Galanter, Marc, editor. | Kleber, Herbert D., editor. | American Psychiatric Association Publishing, issuing body.

Title: The American Psychiatric Association Publishing textbook of substance use disorder treatment / edited by Kathleen T. Brady, Frances R. Levin, Marc Galanter, Herbert D. Kleber.

Other titles: American Psychiatric Publishing textbook of substance abuse treatment | Textbook of substance use disorder treatment

Description: Sixth edition. | Washington, DC : American Psychiatric Association Publishing, [2021] |Preceded by American Psychiatric Publishing textbook of substance abuse treatment. Fifth edition. Washington, DC : American Psychiatric Publishing, 2015. | Includes bibliographical references and index.

Identifiers: LCCN 2020046613 (print) | LCCN 2020046614 (ebook) | ISBN 9781615372218 (hardcover ; alk. paper) | ISBN 9781615373536 (ebook)

Subjects: MESH: Substance-Related Disorderstherapy | Behavior, Addictivetherapy

Classification: LCC RC564 (print) | LCC RC564 (ebook) | NLM WM 270 | DDC 362.29dc23

LC record available at https://lccn.loc.gov/2020046613

LC ebook record available at https://lccn.loc.gov/2020046614

British Library Cataloguing in Publication Data
A CIP record is available from the British Library.

In Memoriam: Herbert D. Kleber, M.D.

We are dedicating this Sixth Edition Textbook to the memory of Dr. Herbert D. Kleber, who passed away on October 5, 2018. From 1994 on, Dr. Kleber coedited the first five editions of this Textbook, embodying in it his command of the research base and the clinical practice of addiction medicine, which he had achieved over five decades of leadership in the field. His particular contribution was his support of empirical research to drive substance use disorder treatment. He thereby firmly established the credibility of this research in the discipline of medical practice overall, as well as its central role in the countrys approach to combating this leading public health problem.

Dr. Kleber began his career in addiction medicine while serving in the U.S. Public Health Services first narcotic treatment center, in Lexington, Kentucky. He drew on his experience there to establish the drug dependence program at Yale University, where he framed the concept of an academic center focused on substance use disorders that combined research, education, and progressive clinical care. He thereby created a setting for training a generation of academic leaders who now serve across the country and worldwide.

Among his many accomplishments, Dr. Kleber was a pioneering influence in developing new solutions to the practical problems of substance use disorder treatment in the New Haven community. Given these achievements and his academic leadership, he was asked to serve as Deputy Director for Demand Reduction at the White House Office of National Drug Control Policy, where he had an important impact on improving treatment for one of the countrys most highly compromised populations.

Dr. Kleber later went on to take the lead in establishing the Substance Abuse Division (now the Division on Substance Use Disorders) at Columbia University, where he wedded a major academic setting to a policy institute. There, he framed innovative approaches to understanding and treating the diversity of substance use disorders, from alcohol to opiates, psychostimulants, and marijuana. For all of these contributions, among his many honors, he was elected to the Institute of Medicine (now called the National Academy of Medicine). He will be sorely missed by many as a major leader and mentor in the addiction field.

Kathleen Brady, M.D., Ph.D.
Frances R. Levin, M.D.
Marc Galanter, M.D.

1. PART I
   The Basis of Substance-Related and Addictive Disorders
2. George F. Koob, Ph.D.
3. Nora D. Volkow, M.D.
4. Joel Gelernter, M.D.
5. Renato Polimanti, Ph.D.
6. Nathan D.L. Smith, A.L.M.
7. Linda B. Cottler, Ph.D., M.P.H., FACE
8. Deborah S. Hasin, Ph.D.
9. Farren R.R. Larson, M.A.
10. PART II
    Assessment and Treatment
11. Timothy Fong, M.D.
12. Richard Saitz, M.D., M.P.H., FACP, DFASAM
13. Jenna L. McCauley, Ph.D.
14. A. Thomas McLellan, Ph.D.
15. PART III
    Specific Substances of Abuse: Neurobiology and Pharmacotherapy
16. Markus Heilig, M.D., Ph.D.
17. Rainer Spanagel, Ph.D.
18. Alyssa Braxton, M.D.
19. Tara M. Wright, M.D.
20. Hugh Myrick, M.D.
21. Mehmet Sofuoglu, M.D., Ph.D.
22. Elise E. DeVito, Ph.D.
23. Thomas R. Kosten, M.D.
24. Richard A. Rawson, Ph.D.
25. Kristen Schmidt, M.D.
26. Larissa J. Mooney, M.D.
27. Jermaine D. Jones, Ph.D.
28. Charles J. Levin, B.A.
29. Mudassir Mumtaz, B.S.
30. Sandra D. Comer, Ph.D.
31. Eric C. Strain, M.D.
32. Kenneth B. Stoller, M.D.
33. Michael Capata, M.D.
34. Karen J. Hartwell, M.D.
35. Elias Dakwar, M.D.
36. Gregory Sahlem, M.D.
37. Brian Sherman, Ph.D.
38. Aimee McRae-Clark, Pharm.D.
39. Christina Brezing, M.D.
40. Souparno Mitra, M.D.
41. Frances R. Levin, M.D.
42. Noah R. Gubner, Ph.D.
43. Neal L. Benowitz, M.D.
44. Jill M. Williams, M.D.
45. Nina Cooperman, Psy.D.
46. Vamsee Chaguturu, M.D.
47. Jennifer L. Jones, M.D.
48. Amy VandenBerg, Pharm.D., BCPP
49. Robert Malcolm, M.D.
50. Harrison G. Pope Jr., M.D.
51. Gen Kanayama, M.D., Ph.D.
52. PART IV
    Nonpharmacotherapeutic Treatment Modalities
53. Edward J. Khantzian, M.D.